Evolution of a bosonic mode across the superconducting dome in the high-Tc cuprate Pr(2-x)Ce(x)CuO(4-{\delta})

We report a detailed spectroscopic study of the electron doped cuprate superconductor Pr(2-x)Ce(x)CuO(4-{\delta}) using point contact junctions for x=0.125(underdoped), x=0.15(optimally doped) and x=0.17(overdoped). From our conductance measurements we are able to identify bosonic resonances for each doping. These excitations disappear above the critical temperature, and above the critical magnetic field. We find that the energy of the bosonic excitations decreases with doping, which excludes lattice vibrations as the paring glue. We conclude that the bosonic mediator for these cuprates is more likely to be spin excitations.Comment: 4 page

Instability of Myelin Tubes under Dehydration: deswelling of layered cylindrical structures

We report experimental observations of an undulational instability of myelin figures. Motivated by this, we examine theoretically the deformation and possible instability of concentric, cylindrical, multi-lamellar membrane structures. Under conditions of osmotic stress (swelling or dehydration), we find a stable, deformed state in which the layer deformation is given by \delta R ~ r^{\sqrt{B_A/(hB)}}, where B_A is the area compression modulus, B is the inter-layer compression modulus, and h is the repeat distance of layers. Also, above a finite threshold of dehydration (or osmotic stress), we find that the system becomes unstable to undulations, first with a characteristic wavelength of order \sqrt{xi d_0}, where xi is the standard smectic penetration depth and d_0 is the thickness of dehydrated region.Comment: 5 pages + 3 figures [revtex 4

Migration routes of the Double-wattled Cassowary

This is where the abstract of this record would appear. This is only demonstration data

Anomalous Enhancement of the Superconducting Transition Temperature in Electron-Doped Cuprate Heterostructures

The superconducting transition temperature $T_{c}$ of multilayers of electron-doped cuprates, composed of underdoped (or undoped) and overdoped La% $_{2-x}$Ce$_{x}$CuO$_{4}$ (LCCO) and Pr$_{2-x}$Ce$_{x}$CuO$_{4}$ (PCCO) thin films, is found to increase significantly with respect to the $T_{c}$ of the corresponding single-phase films. By investigating the critical current density of superlattices with different doping levels and layer thicknesses, we find that the $T_{c}$ enhancement is caused by a redistribution of charge over an anomalously large distance.Comment: 4 figures. To appear in PRB as a Rapid Communicatio

Probing the surface states in Bi2Se3 using the Shubnikov-de Haas effect

Shubnikov-de Haas (SdH) oscillations are observed in Bi2Se3 flakes with high carrier concentration and low bulk mobility. These oscillations probe the protected surface states and enable us to extract their carrier concentration, effective mass and Dingle temperature. The Fermi momentum obtained is in agreement with angle resolved photoemission spectroscopy (ARPES) measurements performed on crystals from the same batch. We study the behavior of the Berry phase as a function of magnetic field. The standard theoretical considerations fail to explain the observed behavior.Comment: 6 pages, 8 figures. Accepted to Physical Review

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials

Lebrikizumab, a high-affinity IgG-4 monoclonal antibody targeting interleukin (IL)-13, selectively prevents the formation of the IL-13Ra1/IL-4Ra heterodimer receptor signalling complex. Lebrikizumab demonstrated rapid, dose-dependent efficacy and an acceptable safety profile in patients with moderate-to-severe atopic dermatitis (AD) in a phase IIb trial (NCT03443024). Here, we report 16-week efficacy and safety outcomes of lebrikizumab monotherapy in patients with AD from two ongoing 52-week, randomized, double-blinded, placebo-controlled phase III trials – ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). Eligible patients with moderate-to-severe AD [adults and adolescents (12–17 years of age, weighing ≥40 kg)] were randomized 2: 1 to subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. Efficacy analyses included proportions of patients achieving Investigator’s Global Assessment (IGA) 0/1, Eczema Area and Severity Index (EASI)-75 and Pruritus Numerical Rating Scale (NRS) ≥ 4-point improvement from baseline (P ≥ 4) at week 16. Nonefficacy-related missing data were imputed by multiple imputation. In ADvocate1, proportions of patients treated with lebrikizumab 250 mg (n = 283) and placebo (n = 141) achieving IGA 0/1 at week 16 were 43.0% and 12.8% (P \u3c 0.001); EASI-75 responses were 59.3% and 16.4% (P \u3c 0.001); P ≥ 4 proportions were 46.3% and 12.7% (P \u3c 0.001), respectively. In ADvocate2 (lebrikizumab, n = 281; placebo, n = 146), corresponding proportions for IGA 0/1 were 33.1% and 10.9% (P \u3c 0.001); EASI-75 responses were 50.8% and 18.2% (P \u3c 0.001); P ≥ 4 proportions were 38.3% and 11.3% (P \u3c 0.001), respectively. The percentage of patients reporting ≥1 TEAE was comparable in ADvocate1 (lebrikizumab, 45.4%; placebo, 51.1%) and ADvocate2 (lebrikizumab 53.0%; placebo 66.2%). Data from two ongoing pivotal phase III trials suggest that lebrikizumab 250 mg Q2W provides an efficacious treatment option with an acceptable safety profile for patients with moderate-to-severe AD